Paper Details

  1. Home
  2. Paper Details

Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease.

Author: AskariFred, BrewerGeorge J, CarlsonMartha, DickRobert B, FinkJohn K, HederaPeter, KluinKaren J, LorinczMatthew T, MorettiPaolo, SchilskyMichael, SitterlyJulia, TankanowRoberta

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

Tetrathiomolybdate is a better choice than trientine for preserving neurologic function in patients with the neurologic presentation of Wilson disease. Tetrathiomolybdate was associated with fewer instances of neurologic deterioration and fewer adverse events, including anemia and leukopenia.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To compare tetrathiomolybdate and trientine in treating patients with the neurologic presentation of Wilson disease for the frequency of neurologic worsening, adverse effects, and degree of neurologic recovery. DESIGN: A randomized, double-blind, controlled, 2-arm study of 48 patients wi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1001/archneur.63.4.521

データ提供：米国国立医学図書館（NLM）

Navigating the Desert of Wilson Disease: Comparing Treatment Options

Wilson disease, a rare genetic disorder affecting copper metabolism, can be a challenging journey, much like traversing a vast and unforgiving desert. This research investigates the effectiveness of two common treatments for Wilson disease, tetrathiomolybdate and trientine, comparing their impact on neurologic symptoms, adverse effects, and overall patient outcomes. The researchers meticulously designed a double-blind study to ensure a fair and accurate comparison of these two treatment options.

A Beacon of Hope for a Rare Disorder

The research found that tetrathiomolybdate was more effective than trientine in preserving neurologic function in patients with Wilson disease. While both treatments were associated with some adverse effects, tetrathiomolybdate was less likely to lead to neurologic deterioration. This finding provides valuable guidance for healthcare professionals, helping them navigate the desert of Wilson disease with greater confidence and precision.

Choosing the Right Path in the Desert of Wilson Disease

This research highlights the importance of carefully considering treatment options for Wilson disease, a challenging condition that requires specialized care. By understanding the relative effectiveness of different medications, healthcare professionals can make informed decisions, tailoring treatment plans to suit each individual patient's needs. This research provides a valuable tool for navigating the complex landscape of Wilson disease, offering a beacon of hope for patients and their families.

Dr.Camel's Conclusion

This research illuminates the importance of finding the right path in the desert of Wilson disease. By comparing the effectiveness of different treatment options, we can provide patients with the best possible care, maximizing their chances of navigating this challenging condition and achieving a positive outcome. This study underscores the critical role of research in improving healthcare outcomes for even the rarest of disorders.

Date :
  1. Date Completed 2006-05-22
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

16606763

DOI: Digital Object Identifier

10.1001/archneur.63.4.521

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.